<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 01 May 2024 04:10:31 +0000</lastbuilddate>
<pubDate>Tue, 30 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Caring for patients with lower extremity artery disease: going beyond stents and bypass grafts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38687682/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 30:ehae195. doi: 10.1093/eurheartj/ehae195. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38687682/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38687682</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae195>10.1093/eurheartj/ehae195</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38687682</guid>
<pubDate>Tue, 30 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Victor Aboyans</dc:creator>
<dc:creator>Marco De Carlo</dc:creator>
<dc:date>2024-04-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Caring for patients with lower extremity artery disease: going beyond stents and bypass grafts</dc:title>
<dc:identifier>pmid:38687682</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae195</dc:identifier>
</item>
<item>
<title>Spatiotemporal ATF3 Expression Determines VSMC Fate in Abdominal Aortic Aneurysm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38686580/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our results demonstrate a previously unrecognized role of ATF3 in AAA development and progression, and ATF3 may serve as a novel therapeutic and prognostic marker for AAA.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 30. doi: 10.1161/CIRCRESAHA.124.324323. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Abdominal aortic aneurysm (AAA) is a catastrophic disease with little effective therapy, likely due to the limited understanding of the mechanisms underlying AAA development and progression. Activating transcription factor (ATF) 3 has been increasingly recognized as a key regulator of cardiovascular diseases. However, the role of ATF3 (activating transcription factor 3) in AAA development and progression remains elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Genome-wide RNA sequencing analysis was performed on the aorta isolated from saline or Ang II (angiotensin II)-induced AAA mice, and ATF3 was identified as the potential key gene for AAA development. To examine the role of ATF3 in AAA development, vascular smooth muscle cell-specific ATF3 knockdown or overexpressed mice by recombinant adenoassociated virus serotype 9 vectors carrying ATF3, or shRNA-ATF3 with SM22α (smooth muscle protein 22-α) promoter were used in Ang II (angiotensin II)-induced AAA mice. In human and murine vascular smooth muscle cells, gain or loss of function experiments were performed to investigate the role of ATF3 in vascular smooth muscle cell proliferation and apoptosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In both Ang II-induced AAA mice and patients with AAA, the expression of ATF3 was reduced in aneurysm tissues but increased in aortic lesion tissues. The deficiency of ATF3 in vascular smooth muscle cell promoted AAA formation in Ang II-induced AAA mice. PDGFRB (platelet-derived growth factor receptor β) was identified as the target of ATF3, which mediated vascular smooth muscle cell proliferation in response to TNF-alpha (tumor necrosis factor-α) at the early stage of AAA. ATF3 suppressed the mitochondria-dependent apoptosis at the advanced stage by upregulating its direct target BCL2. Our chromatin immunoprecipitation results also demonstrated that the recruitment of NFκB1 and P300/BAF/H3K27ac complex to the ATF3 promoter induces ATF3 transcription via enhancer activation. NFKB1 inhibitor (andrographolide) inhibits the expression of ATF3 by blocking the recruiters NFKB1 and ATF3-enhancer to the ATF3-promoter region, ultimately leading to AAA development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results demonstrate a previously unrecognized role of ATF3 in AAA development and progression, and ATF3 may serve as a novel therapeutic and prognostic marker for AAA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38686580/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38686580</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324323>10.1161/CIRCRESAHA.124.324323</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38686580</guid>
<pubDate>Tue, 30 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Ying Wen</dc:creator>
<dc:creator>Yingying Liu</dc:creator>
<dc:creator>Qiang Li</dc:creator>
<dc:creator>Jinlin Tan</dc:creator>
<dc:creator>Xing Fu</dc:creator>
<dc:creator>Yiwen Liang</dc:creator>
<dc:creator>Yonghua Tuo</dc:creator>
<dc:creator>Luhao Liu</dc:creator>
<dc:creator>Xueqiong Zhou</dc:creator>
<dc:creator>Dongkai LiuFu</dc:creator>
<dc:creator>Xuejiao Fan</dc:creator>
<dc:creator>Chaofei Chen</dc:creator>
<dc:creator>Zheng Chen</dc:creator>
<dc:creator>Zhouping Wang</dc:creator>
<dc:creator>Shunyang Fan</dc:creator>
<dc:creator>Renjing Liu</dc:creator>
<dc:creator>Lei Pan</dc:creator>
<dc:creator>Yuan Zhang</dc:creator>
<dc:creator>Wai Ho Tang</dc:creator>
<dc:date>2024-04-30</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Spatiotemporal ATF3 Expression Determines VSMC Fate in Abdominal Aortic Aneurysm</dc:title>
<dc:identifier>pmid:38686580</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324323</dc:identifier>
</item>
<item>
<title>Rectifying METTL4-Mediated N&lt;sup>;6&lt;/sup>;-Methyladenine Excess in Mitochondrial DNA Alleviates Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38686562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings identify a pivotal role of cardiomyocyte mtDNA 6mA and the corresponding methyltransferase, METTL4, in the pathogenesis of mitochondrial dysfunction and HF. Targeted suppression of METTL4 to rectify mtDNA 6mA excess emerges as a promising strategy for developing mitochondria-focused HF interventions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30. doi: 10.1161/CIRCULATIONAHA.123.068358. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Myocardial mitochondrial dysfunction underpins the pathogenesis of heart failure (HF), yet therapeutic options to restore myocardial mitochondrial function are scarce. Epigenetic modifications of mitochondrial DNA (mtDNA), such as methylation, play a pivotal role in modulating mitochondrial homeostasis. However, their involvement in HF remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Experimental HF models were established through continuous angiotensin II and phenylephrine (AngII/PE) infusion or prolonged myocardial ischemia/reperfusion injury. The landscape of N<sup>6</sup>-methyladenine (6mA) methylation within failing cardiomyocyte mtDNA was characterized using high-resolution mass spectrometry and methylated DNA immunoprecipitation sequencing. A tamoxifen-inducible cardiomyocyte-specific <i>Mettl4</i> knockout mouse model and adeno-associated virus vectors designed for cardiomyocyte-targeted manipulation of METTL4 (methyltransferase-like protein 4) expression were used to ascertain the role of mtDNA 6mA and its methyltransferase METTL4 in HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: METTL4 was predominantly localized within adult cardiomyocyte mitochondria. 6mA modifications were significantly more abundant in mtDNA than in nuclear DNA. Postnatal cardiomyocyte maturation presented with a reduction in 6mA levels within mtDNA, coinciding with a decrease in METTL4 expression. However, an increase in both mtDNA 6mA level and METTL4 expression was observed in failing adult cardiomyocytes, suggesting a shift toward a neonatal-like state. METTL4 preferentially targeted mtDNA promoter regions, which resulted in interference with transcription initiation complex assembly, mtDNA transcriptional stalling, and ultimately mitochondrial dysfunction. Amplifying cardiomyocyte mtDNA 6mA through METTL4 overexpression led to spontaneous mitochondrial dysfunction and HF phenotypes. The transcription factor p53 was identified as a direct regulator of METTL4 transcription in response to HF-provoking stress, thereby revealing a stress-responsive mechanism that controls METTL4 expression and mtDNA 6mA. Cardiomyocyte-specific deletion of the <i>Mettl4</i> gene eliminated mtDNA 6mA excess, preserved mitochondrial function, and mitigated the development of HF upon continuous infusion of AngII/PE. In addition, specific silencing of METTL4 in cardiomyocytes restored mitochondrial function and offered therapeutic relief in mice with preexisting HF, irrespective of whether the condition was induced by AngII/PE infusion or myocardial ischemia/reperfusion injury.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings identify a pivotal role of cardiomyocyte mtDNA 6mA and the corresponding methyltransferase, METTL4, in the pathogenesis of mitochondrial dysfunction and HF. Targeted suppression of METTL4 to rectify mtDNA 6mA excess emerges as a promising strategy for developing mitochondria-focused HF interventions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38686562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38686562</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068358>10.1161/CIRCULATIONAHA.123.068358</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38686562</guid>
<pubDate>Tue, 30 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Fuyang Zhang</dc:creator>
<dc:creator>Ling Zhang</dc:creator>
<dc:creator>Guangyu Hu</dc:creator>
<dc:creator>Xiyao Chen</dc:creator>
<dc:creator>Hui Liu</dc:creator>
<dc:creator>Congye Li</dc:creator>
<dc:creator>Xiong Guo</dc:creator>
<dc:creator>Chong Huang</dc:creator>
<dc:creator>Fangfang Sun</dc:creator>
<dc:creator>Tongzheng Li</dc:creator>
<dc:creator>Zhe Cui</dc:creator>
<dc:creator>Yongzhen Guo</dc:creator>
<dc:creator>Wenjun Yan</dc:creator>
<dc:creator>Yunlong Xia</dc:creator>
<dc:creator>Zhiyuan Liu</dc:creator>
<dc:creator>Zhen Lin</dc:creator>
<dc:creator>Weixun Duan</dc:creator>
<dc:creator>Linhe Lu</dc:creator>
<dc:creator>Xinyi Wang</dc:creator>
<dc:creator>Zhengyang Wang</dc:creator>
<dc:creator>Shan Wang</dc:creator>
<dc:creator>Ling Tao</dc:creator>
<dc:date>2024-04-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Rectifying METTL4-Mediated N&lt;sup>;6&lt;/sup>;-Methyladenine Excess in Mitochondrial DNA Alleviates Heart Failure</dc:title>
<dc:identifier>pmid:38686562</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068358</dc:identifier>
</item>
<item>
<title>Atherosclerosis Is a Smooth Muscle Cell-Driven Tumor-Like Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38686559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings demonstrate that atherosclerosis is an SMC-driven tumor-like disease, advancing our understanding of its pathogenesis and opening prospects for innovative precision molecular strategies aimed at preventing and treating atherosclerotic cardiovascular disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30. doi: 10.1161/CIRCULATIONAHA.123.067587. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atherosclerosis, a leading cause of cardiovascular disease, involves the pathological activation of various cell types, including immunocytes (eg, macrophages and T cells), smooth muscle cells (SMCs), and endothelial cells. Accumulating evidence suggests that transition of SMCs to other cell types, known as phenotypic switching, plays a central role in atherosclerosis development and complications. However, the characteristics of SMC-derived cells and the underlying mechanisms of SMC transition in disease pathogenesis remain poorly understood. Our objective is to characterize tumor cell-like behaviors of SMC-derived cells in atherosclerosis, with the ultimate goal of developing interventions targeting SMC transition for the prevention and treatment of atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used SMC lineage tracing mice and human tissues and applied a range of methods, including molecular, cellular, histological, computational, human genetics, and pharmacological approaches, to investigate the features of SMC-derived cells in atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: SMC-derived cells in mouse and human atherosclerosis exhibit multiple tumor cell-like characteristics, including genomic instability, evasion of senescence, hyperproliferation, resistance to cell death, invasiveness, and activation of comprehensive cancer-associated gene regulatory networks. Specific expression of the oncogenic mutant <i>Kras</i><sup><i>G12D</i></sup> in SMCs accelerates phenotypic switching and exacerbates atherosclerosis. Furthermore, we provide proof of concept that niraparib, an anticancer drug targeting DNA damage repair, attenuates atherosclerosis progression and induces regression of lesions in advanced disease in mouse models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings demonstrate that atherosclerosis is an SMC-driven tumor-like disease, advancing our understanding of its pathogenesis and opening prospects for innovative precision molecular strategies aimed at preventing and treating atherosclerotic cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38686559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38686559</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067587>10.1161/CIRCULATIONAHA.123.067587</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38686559</guid>
<pubDate>Tue, 30 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Huize Pan</dc:creator>
<dc:creator>Sebastian E Ho</dc:creator>
<dc:creator>Chenyi Xue</dc:creator>
<dc:creator>Jian Cui</dc:creator>
<dc:creator>Quinian S Johanson</dc:creator>
<dc:creator>Nadja Sachs</dc:creator>
<dc:creator>Leila S Ross</dc:creator>
<dc:creator>Fang Li</dc:creator>
<dc:creator>Robert A Solomon</dc:creator>
<dc:creator>E Sander Connolly</dc:creator>
<dc:creator>Virendra I Patel</dc:creator>
<dc:creator>Lars Maegdefessel</dc:creator>
<dc:creator>Hanrui Zhang</dc:creator>
<dc:creator>Muredach P Reilly</dc:creator>
<dc:date>2024-04-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Atherosclerosis Is a Smooth Muscle Cell-Driven Tumor-Like Disease</dc:title>
<dc:identifier>pmid:38686559</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067587</dc:identifier>
</item>
<item>
<title>Atherosclerotic plaque-specific methylation biomarkers in plasma cell-free DNA of female and male patients with coronary artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38685672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 30:ehae156. doi: 10.1093/eurheartj/ehae156. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38685672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38685672</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae156>10.1093/eurheartj/ehae156</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38685672</guid>
<pubDate>Tue, 30 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Ernest Diez Benavente</dc:creator>
<dc:creator>Tim R Sakkers</dc:creator>
<dc:creator>Pim van der Harst</dc:creator>
<dc:creator>Hester M den Ruijter</dc:creator>
<dc:date>2024-04-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atherosclerotic plaque-specific methylation biomarkers in plasma cell-free DNA of female and male patients with coronary artery disease</dc:title>
<dc:identifier>pmid:38685672</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae156</dc:identifier>
</item>
<item>
<title>Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38685132/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>One in six ischaemic stroke patients has an embolic stroke of undetermined source (ESUS), defined as a stroke with unclear aetiology despite recommended diagnostic evaluation. The overall cardiovascular risk of ESUS is high and it is important to optimize strategies to prevent recurrent stroke and other cardiovascular events. The aim of clinicians when confronted with a patient not only with ESUS but also with any other medical condition of unclear aetiology is to identify the actual cause...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 30:ehae150. doi: 10.1093/eurheartj/ehae150. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">One in six ischaemic stroke patients has an embolic stroke of undetermined source (ESUS), defined as a stroke with unclear aetiology despite recommended diagnostic evaluation. The overall cardiovascular risk of ESUS is high and it is important to optimize strategies to prevent recurrent stroke and other cardiovascular events. The aim of clinicians when confronted with a patient not only with ESUS but also with any other medical condition of unclear aetiology is to identify the actual cause amongst a list of potential differential diagnoses, in order to optimize secondary prevention. However, specifically in ESUS, this may be challenging as multiple potential thromboembolic sources frequently coexist. Also, it can be delusively reassuring because despite the implementation of specific treatments for the individual pathology presumed to be the actual thromboembolic source, patients can still be vulnerable to stroke and other cardiovascular events caused by other pathologies already identified during the index diagnostic evaluation but whose thromboembolic potential was underestimated. Therefore, rather than trying to presume which particular mechanism is the actual embolic source in an ESUS patient, it is important to assess the overall thromboembolic risk of the patient through synthesis of the individual risks linked to all pathologies present, regardless if presumed causally associated or not. In this paper, a multi-disciplinary panel of clinicians/researchers from various backgrounds of expertise and specialties (cardiology, internal medicine, neurology, radiology and vascular surgery) proposes a comprehensive multi-dimensional assessment of the overall thromboembolic risk in ESUS patients through the composition of individual risks associated with all prevalent pathologies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38685132/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38685132</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae150>10.1093/eurheartj/ehae150</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38685132</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>George Ntaios</dc:creator>
<dc:creator>Helmut Baumgartner</dc:creator>
<dc:creator>Wolfram Doehner</dc:creator>
<dc:creator>Erwan Donal</dc:creator>
<dc:creator>Thor Edvardsen</dc:creator>
<dc:creator>Jeff S Healey</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Hooman Kamel</dc:creator>
<dc:creator>Scott E Kasner</dc:creator>
<dc:creator>Eleni Korompoki</dc:creator>
<dc:creator>Babak B Navi</dc:creator>
<dc:creator>Christian Pristipino</dc:creator>
<dc:creator>Luca Saba</dc:creator>
<dc:creator>Renate B Schnabel</dc:creator>
<dc:creator>Emma Svennberg</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC</dc:title>
<dc:identifier>pmid:38685132</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae150</dc:identifier>
</item>
<item>
<title>Unraveling the Unsolved Mysteries of the Athletic Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683901/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1416-1418. doi: 10.1161/CIRCULATIONAHA.124.064534. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683901/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38683901</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.064534>10.1161/CIRCULATIONAHA.124.064534</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683901</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>William K Cornwell</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Unraveling the Unsolved Mysteries of the Athletic Heart</dc:title>
<dc:identifier>pmid:38683901</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.064534</dc:identifier>
</item>
<item>
<title>Empowering Valvular Heart Disease Research With Stem Cell-Derived Valve Cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683900/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1457-1460. doi: 10.1161/CIRCULATIONAHA.124.068656. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683900/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38683900</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068656>10.1161/CIRCULATIONAHA.124.068656</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683900</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Mengcheng Shen</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Empowering Valvular Heart Disease Research With Stem Cell-Derived Valve Cells</dc:title>
<dc:identifier>pmid:38683900</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068656</dc:identifier>
</item>
<item>
<title>Global Rounds: Cardiovascular Care in Australia and New Zealand</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683899/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1402-1404. doi: 10.1161/CIRCULATIONAHA.123.064271. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683899/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38683899</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064271>10.1161/CIRCULATIONAHA.123.064271</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683899</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarah Zaman</dc:creator>
<dc:creator>Nicola C Edwards</dc:creator>
<dc:creator>Derek P Chew</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Global Rounds: Cardiovascular Care in Australia and New Zealand</dc:title>
<dc:identifier>pmid:38683899</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064271</dc:identifier>
</item>
<item>
<title>Peripheral Oxygenation and Pulmonary Hemodynamics in Individuals With Fontan Circulation During 24-Hour High-Altitude Exposure Simulation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683898/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1466-1468. doi: 10.1161/CIRCULATIONAHA.123.067601. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683898/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38683898</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067601>10.1161/CIRCULATIONAHA.123.067601</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683898</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Nicole Müller</dc:creator>
<dc:creator>Julian Alexander Härtel</dc:creator>
<dc:creator>Jan Schmitz</dc:creator>
<dc:creator>Ute Baur</dc:creator>
<dc:creator>Melanie von der Wiesche</dc:creator>
<dc:creator>Iris Rieger</dc:creator>
<dc:creator>Darius Gerlach</dc:creator>
<dc:creator>Jon von Stritzky</dc:creator>
<dc:creator>Anja Bach</dc:creator>
<dc:creator>Christopher Hart</dc:creator>
<dc:creator>Janina Bros</dc:creator>
<dc:creator>Benedikt Seeger</dc:creator>
<dc:creator>Emily Zollmann</dc:creator>
<dc:creator>Marijke Grau</dc:creator>
<dc:creator>Boris Dragutinovic</dc:creator>
<dc:creator>Laura-Maria de Boni</dc:creator>
<dc:creator>Jan-Niklas Hönemann</dc:creator>
<dc:creator>Wilhelm Bloch</dc:creator>
<dc:creator>Daniel Aeschbach</dc:creator>
<dc:creator>Eva-Maria Elmenhorst</dc:creator>
<dc:creator>Ulrike Herberg</dc:creator>
<dc:creator>Alena Hess</dc:creator>
<dc:creator>Moritz Schumann</dc:creator>
<dc:creator>Tobias Kratz</dc:creator>
<dc:creator>Jens Jordan</dc:creator>
<dc:creator>Johannes Breuer</dc:creator>
<dc:creator>Jens Tank</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Peripheral Oxygenation and Pulmonary Hemodynamics in Individuals With Fontan Circulation During 24-Hour High-Altitude Exposure Simulation</dc:title>
<dc:identifier>pmid:38683898</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067601</dc:identifier>
</item>
<item>
<title>Response by Kelham et al to Letter Regarding Article, "Computed Tomography Cardiac Angiography Before Invasive Coronary Angiography in Patients With Previous Bypass Surgery: The BYPASS-CTCA Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683897/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):e1133. doi: 10.1161/CIRCULATIONAHA.124.068825. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683897/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38683897</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068825>10.1161/CIRCULATIONAHA.124.068825</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683897</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew Kelham</dc:creator>
<dc:creator>Anthony Mathur</dc:creator>
<dc:creator>Daniel A Jones</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Kelham et al to Letter Regarding Article, "Computed Tomography Cardiac Angiography Before Invasive Coronary Angiography in Patients With Previous Bypass Surgery: The BYPASS-CTCA Trial"</dc:title>
<dc:identifier>pmid:38683897</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068825</dc:identifier>
</item>
<item>
<title>Adult Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683896/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1397-1399. doi: 10.1161/CIRCULATIONAHA.123.066983. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683896/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38683896</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066983>10.1161/CIRCULATIONAHA.123.066983</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683896</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Mikael Dellborg</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Adult Congenital Heart Disease</dc:title>
<dc:identifier>pmid:38683896</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066983</dc:identifier>
</item>
<item>
<title>Letter by Apostolos et al Regarding Article, "Computed Tomography Cardiac Angiography Before Invasive Coronary Angiography in Patients With Previous Bypass Surgery: The BYPASS-CTCA Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683895/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):e1132. doi: 10.1161/CIRCULATIONAHA.123.067850. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683895/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38683895</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067850>10.1161/CIRCULATIONAHA.123.067850</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683895</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Anastasios Apostolos</dc:creator>
<dc:creator>Grigoris V Karamasis</dc:creator>
<dc:creator>Grigorios Tsigkas</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Apostolos et al Regarding Article, "Computed Tomography Cardiac Angiography Before Invasive Coronary Angiography in Patients With Previous Bypass Surgery: The BYPASS-CTCA Trial"</dc:title>
<dc:identifier>pmid:38683895</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067850</dc:identifier>
</item>
<item>
<title>Fossil Fuels, Climate Change, and Cardiovascular Disease: A Call to Action</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683894/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1400-1401. doi: 10.1161/CIRCULATIONAHA.123.065904. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683894/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38683894</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065904>10.1161/CIRCULATIONAHA.123.065904</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683894</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Caren G Solomon</dc:creator>
<dc:creator>Philip J Landrigan</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Fossil Fuels, Climate Change, and Cardiovascular Disease: A Call to Action</dc:title>
<dc:identifier>pmid:38683894</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065904</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683893/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1461-1465. doi: 10.1161/CIRCULATIONAHA.124.069841. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683893/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38683893</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069841>10.1161/CIRCULATIONAHA.124.069841</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683893</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:38683893</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069841</dc:identifier>
</item>
<item>
<title>ABCG2-Expressing Clonal Repopulating Endothelial Cells Serve to Form and Maintain Blood Vessels</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38682338/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results are the first to establish that a single prospective marker identifies CRECs in mice and human individuals, which holds promise to provide new cell therapies for repair of damaged vessels in patients with endothelial dysfunction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 29. doi: 10.1161/CIRCULATIONAHA.122.061833. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Most organs are maintained lifelong by resident stem/progenitor cells. During development and regeneration, lineage-specific stem/progenitor cells can contribute to the growth or maintenance of different organs, whereas fully differentiated mature cells have less regenerative potential. However, it is unclear whether vascular endothelial cells (ECs) are also replenished by stem/progenitor cells with EC-repopulating potential residing in blood vessels. It has been reported recently that some EC populations possess higher clonal proliferative potential and vessel-forming capacity compared with mature ECs. Nevertheless, a marker to identify vascular clonal repopulating ECs (CRECs) in murine and human individuals is lacking, and, hence, the mechanism for the proliferative, self-renewal, and vessel-forming potential of CRECs is elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We analyzed colony-forming, self-renewal, and vessel-forming potential of ABCG2 (ATP binding cassette subfamily G member 2)-expressing ECs in human umbilical vessels. To study the contribution of <i>Abcg2</i>-expressing ECs to vessel development and regeneration, we developed Abcg2Cre<sup>Ert2</sup>;ROSA TdTomato mice and performed lineage tracing during mouse development and during tissue regeneration after myocardial infarction injury. RNA sequencing and chromatin methylation chromatin immunoprecipitation followed by sequencing were conducted to study the gene regulation in <i>Abcg2</i>-expressing ECs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In human and mouse vessels, ECs with higher <i>ABCG2</i> expression (ABCECs) possess higher clonal proliferative potential and in vivo vessel-forming potential compared with mature ECs. These cells could clonally contribute to vessel formation in primary and secondary recipients after transplantation. These features of ABCECs meet the criteria of CRECs. Results from lineage tracing experiments confirm that <i>Abcg2</i>-expressing CRECs (<i>Abc</i>CRECs) contribute to arteries, veins, and capillaries in cardiac tissue development and vascular tissue regeneration after myocardial infarction. Transcriptome and epigenetic analyses reveal that a gene expression signature involved in angiogenesis and vessel development is enriched in <i>Abc</i>CRECs. In addition, various angiogenic genes, such as <i>Notch2</i> and <i>Hey2</i>, are bivalently modified by trimethylation at the 4th and 27th lysine residue of histone H3 (H3K4me3 and H3K27me3) in <i>Abc</i>CRECs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results are the first to establish that a single prospective marker identifies CRECs in mice and human individuals, which holds promise to provide new cell therapies for repair of damaged vessels in patients with endothelial dysfunction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38682338/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38682338</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061833>10.1161/CIRCULATIONAHA.122.061833</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38682338</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Yang Lin</dc:creator>
<dc:creator>Chang-Hyun Gil</dc:creator>
<dc:creator>Kimihiko Banno</dc:creator>
<dc:creator>Masataka Yokoyama</dc:creator>
<dc:creator>Matthew Wingo</dc:creator>
<dc:creator>Ellen Go</dc:creator>
<dc:creator>Nutan Prasain</dc:creator>
<dc:creator>Ying Liu</dc:creator>
<dc:creator>Takashi Hato</dc:creator>
<dc:creator>Hisamichi Naito</dc:creator>
<dc:creator>Taku Wakabayashi</dc:creator>
<dc:creator>Musia Sominskaia</dc:creator>
<dc:creator>Meng Gao</dc:creator>
<dc:creator>Kevin Chen</dc:creator>
<dc:creator>Fuqiang Geng</dc:creator>
<dc:creator>Jesus Maria Gomez Salinero</dc:creator>
<dc:creator>Sisi Chen</dc:creator>
<dc:creator>W Christopher Shelley</dc:creator>
<dc:creator>Momoko Yoshimoto</dc:creator>
<dc:creator>Sergio Li Calzi</dc:creator>
<dc:creator>Michael P Murphy</dc:creator>
<dc:creator>Kyoji Horie</dc:creator>
<dc:creator>Maria B Grant</dc:creator>
<dc:creator>Ryan Schreiner</dc:creator>
<dc:creator>David Redmond</dc:creator>
<dc:creator>David P Basile</dc:creator>
<dc:creator>Shahin Rafii</dc:creator>
<dc:creator>Mervin C Yoder</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>ABCG2-Expressing Clonal Repopulating Endothelial Cells Serve to Form and Maintain Blood Vessels</dc:title>
<dc:identifier>pmid:38682338</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.061833</dc:identifier>
</item>
<item>
<title>CAVIN1-Mediated hERG Dynamics: A Novel Mechanism Underlying the Interindividual Variability in Drug-Induced Long QT</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38682330/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study identifies unbridled turnover of the potassium channel hERG as a mechanism supporting the interindividual susceptibility underlying diLQT development and demonstrates how this phenomenon is finely tuned by CAVIN1.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 29. doi: 10.1161/CIRCULATIONAHA.123.063917. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Drug-induced QT prolongation (diLQT) is a feared side effect that could expose susceptible individuals to fatal arrhythmias. The occurrence of diLQT is primarily attributed to unintended drug interactions with cardiac ion channels, notably the hERG (human ether-a-go-go-related gene) channels that generate the delayed-rectifier potassium current (I<sub>Kr</sub>) and thereby regulate the late repolarization phase. There is an important interindividual susceptibility to develop diLQT, which is of unknown origin but can be reproduced in patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs). We aimed to investigate the dynamics of hERG channels in response to sotalol and to identify regulators of the susceptibility to developing diLQT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We measured electrophysiological activity and cellular distribution of hERG channels after hERG blocker treatment in iPS-CMs derived from patients with highest sensitivity (HS) or lowest sensitivity (LS) to sotalol administration in vivo (ie, on the basis of the measure of the maximal change in QT interval 3 hours after administration). Specific small interfering RNAs and CAVIN1-T2A-GFP adenovirus were used to manipulate <i>CAVIN1</i> expression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Whereas HS and LS iPS-CMs showed similar electrophysiological characteristics at baseline, the late repolarization phase was prolonged and I<sub>Kr</sub> significantly decreased after exposure of HS iPS-CMs to low sotalol concentrations. I<sub>Kr</sub> reduction was caused by a rapid translocation of hERG channel from the membrane to the cytoskeleton-associated fractions upon sotalol application. <i>CAVIN1</i>, essential for caveolae biogenesis, was 2× more highly expressed in HS iPS-CMs, and its knockdown by small interfering RNA reduced their sensitivity to sotalol. <i>CAVIN1</i> overexpression in LS iPS-CMs using adenovirus showed reciprocal effects. We found that treatment with sotalol promoted translocation of the hERG channel from the plasma membrane to the cytoskeleton fractions in a process dependent on CAVIN1 (caveolae associated protein 1) expression. <i>CAVIN1</i> silencing reduced the number of caveolae at the membrane and abrogated the translocation of hERG channel in sotalol-treated HS iPS-CMs. CAVIN1 also controlled cardiomyocyte responses to other hERG blockers, such as E4031, vandetanib, and clarithromycin.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study identifies unbridled turnover of the potassium channel hERG as a mechanism supporting the interindividual susceptibility underlying diLQT development and demonstrates how this phenomenon is finely tuned by CAVIN1.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38682330/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38682330</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063917>10.1161/CIRCULATIONAHA.123.063917</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38682330</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Zeina R Al Sayed</dc:creator>
<dc:creator>Céline Pereira</dc:creator>
<dc:creator>Rémi Le Borgne</dc:creator>
<dc:creator>Christine Viaris de Lesegno</dc:creator>
<dc:creator>Charlène Jouve</dc:creator>
<dc:creator>Esthel Pénard</dc:creator>
<dc:creator>Adeline Mallet</dc:creator>
<dc:creator>Nihar Masurkar</dc:creator>
<dc:creator>Gildas Loussouarn</dc:creator>
<dc:creator>Jean-Marc Verbavatz</dc:creator>
<dc:creator>Christophe Lamaze</dc:creator>
<dc:creator>David-Alexandre Trégouët</dc:creator>
<dc:creator>Jean-Sébastien Hulot</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>CAVIN1-Mediated hERG Dynamics: A Novel Mechanism Underlying the Interindividual Variability in Drug-Induced Long QT</dc:title>
<dc:identifier>pmid:38682330</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.063917</dc:identifier>
</item>
<item>
<title>PDZ-Binding Kinase, a Novel Regulator of Vascular Remodeling in Pulmonary Arterial Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38682326/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: PBK is a newly described target for PAH that is upregulated in proliferating PA smooth muscle cells, where it contributes to proliferation through changes in cytokinesis and cell cycle dynamics to promote medial thickening, fibrosis, increased PA resistance, elevated right ventricular systolic pressure, right ventricular remodeling, and PH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 29. doi: 10.1161/CIRCULATIONAHA.123.067095. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Pulmonary arterial hypertension (PAH) is high blood pressure in the lungs that originates from structural changes in small resistance arteries. A defining feature of PAH is the inappropriate remodeling of pulmonary arteries (PA) leading to right ventricle failure and death. Although treatment of PAH has improved, the long-term prognosis for patients remains poor, and more effective targets are needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Gene expression was analyzed by microarray, RNA sequencing, quantitative polymerase chain reaction, Western blotting, and immunostaining of lung and isolated PA in multiple mouse and rat models of pulmonary hypertension (PH) and human PAH. PH was assessed by digital ultrasound, hemodynamic measurements, and morphometry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Microarray analysis of the transcriptome of hypertensive rat PA identified a novel candidate, PBK (PDZ-binding kinase), that was upregulated in multiple models and species including humans. PBK is a serine/threonine kinase with important roles in cell proliferation that is minimally expressed in normal tissues but significantly increased in highly proliferative tissues. PBK was robustly upregulated in the medial layer of PA, where it overlaps with markers of smooth muscle cells. Gain-of-function approaches show that active forms of PBK increase PA smooth muscle cell proliferation, whereas silencing PBK, dominant negative PBK, and pharmacological inhibitors of PBK all reduce proliferation. Pharmacological inhibitors of PBK were effective in PH reversal strategies in both mouse and rat models, providing translational significance. In a complementary genetic approach, PBK was knocked out in rats using CRISPR/Cas9 editing, and loss of PBK prevented the development of PH. We found that PBK bound to PRC1 (protein regulator of cytokinesis 1) in PA smooth muscle cells and that multiple genes involved in cytokinesis were upregulated in experimental models of PH and human PAH. Active PBK increased PRC1 phosphorylation and supported cytokinesis in PA smooth muscle cells, whereas silencing or dominant negative PBK reduced cytokinesis and the number of cells in the G2/M phase of the cell cycle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: PBK is a newly described target for PAH that is upregulated in proliferating PA smooth muscle cells, where it contributes to proliferation through changes in cytokinesis and cell cycle dynamics to promote medial thickening, fibrosis, increased PA resistance, elevated right ventricular systolic pressure, right ventricular remodeling, and PH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38682326/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38682326</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067095>10.1161/CIRCULATIONAHA.123.067095</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38682326</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Zsuzsanna Bordan</dc:creator>
<dc:creator>Robert Batori</dc:creator>
<dc:creator>Stephen Haigh</dc:creator>
<dc:creator>Xueyi Li</dc:creator>
<dc:creator>Mary Louise Meadows</dc:creator>
<dc:creator>Zach L Brown</dc:creator>
<dc:creator>Madison A West</dc:creator>
<dc:creator>Kunzhe Dong</dc:creator>
<dc:creator>Weihong Han</dc:creator>
<dc:creator>Yunchao Su</dc:creator>
<dc:creator>Qian Ma</dc:creator>
<dc:creator>Yuqing Huo</dc:creator>
<dc:creator>Jiliang Zhou</dc:creator>
<dc:creator>Mahmoud Abdelbary</dc:creator>
<dc:creator>Jennifer Sullivan</dc:creator>
<dc:creator>Neal L Weintraub</dc:creator>
<dc:creator>David W Stepp</dc:creator>
<dc:creator>Feng Chen</dc:creator>
<dc:creator>Scott A Barman</dc:creator>
<dc:creator>David J R Fulton</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>PDZ-Binding Kinase, a Novel Regulator of Vascular Remodeling in Pulmonary Arterial Hypertension</dc:title>
<dc:identifier>pmid:38682326</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067095</dc:identifier>
</item>
<item>
<title>Long-term outcomes after hospitalization for atrial fibrillation or flutter</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38678737/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients hospitalized for AF or flutter had high death rates with an average 2.6-year loss in life expectancy. Moreover, re-hospitalizations for AF or flutter and related outcomes such as heart failure and stroke were common with catheter ablation used infrequently for treatment, which warrant further actions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 28:ehae204. doi: 10.1093/eurheartj/ehae204. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Atrial fibrillation (AF) and flutter are common causes of hospitalizations but contemporary long-term outcomes following these episodes are uncertain. This study assessed outcomes up to 10 years after an acute AF or flutter hospitalization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients hospitalized acutely with a primary diagnosis of AF or flutter from 2008-17 from all public and most private hospitals in Australia and New Zealand were included. Kaplan-Meier methods and flexible parametric survival modelling were used to estimate survival and loss in life expectancy, respectively. Competing risk model accounting for death was used when estimating incidence of non-fatal outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 260 492 adults (mean age 70.5 ± 14.4 years, 49.6% female) were followed up for 1 068 009 person-years (PY), during which 69 167 died (incidence rate 6.5/100 PY) with 91.2% survival at 1 year, 72.7% at 5 years, and 55.2% at 10 years. Estimated loss in life expectancy was 2.6 years, or 16.8% of expected life expectancy. Re-hospitalizations for heart failure (2.9/100 PY), stroke (1.7/100 PY), and myocardial infarction (1.1/100 PY) were common with respective cumulative incidences of 16.8%, 11.0%, and 7.1% by 10 years. Re-hospitalization for AF or flutter occurred in 21.3% by 1 year, 35.3% by 5 years, and 41.2% by 10 years (11.6/100 PY). The cumulative incidence of patients undergoing catheter ablation of AF was 6.5% at 10 years (1.2/100 PY).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients hospitalized for AF or flutter had high death rates with an average 2.6-year loss in life expectancy. Moreover, re-hospitalizations for AF or flutter and related outcomes such as heart failure and stroke were common with catheter ablation used infrequently for treatment, which warrant further actions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38678737/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38678737</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae204>10.1093/eurheartj/ehae204</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38678737</guid>
<pubDate>Sun, 28 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Linh Thi Hai Ngo</dc:creator>
<dc:creator>Yang Peng</dc:creator>
<dc:creator>Russell Denman</dc:creator>
<dc:creator>Ian Yang</dc:creator>
<dc:creator>Isuru Ranasinghe</dc:creator>
<dc:date>2024-04-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Long-term outcomes after hospitalization for atrial fibrillation or flutter</dc:title>
<dc:identifier>pmid:38678737</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae204</dc:identifier>
</item>
<item>
<title>Where are cardiology's nuts and bolts to be found?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38676374/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 27:ehae209. doi: 10.1093/eurheartj/ehae209. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38676374/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38676374</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae209>10.1093/eurheartj/ehae209</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38676374</guid>
<pubDate>Sat, 27 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter Lanzer</dc:creator>
<dc:date>2024-04-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Where are cardiology's nuts and bolts to be found?</dc:title>
<dc:identifier>pmid:38676374</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae209</dc:identifier>
</item>
<item>
<title>Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-κB</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38670073/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240501001029&amp;v=2.18.0.post9+e462414
      <description>Nuclear factor κB (NF-κB) plays roles in various diseases. Many inflammatory signals, such as circulating lipopolysaccharides (LPSs), activate NF-κB via specific receptors. Using whole-genome CRISPR-Cas9 screens of LPS-treated cells that express an NF-κB-driven suicide gene, we discovered that the LPS receptor Toll-like receptor 4 (TLR4) is specifically dependent on the oligosaccharyltransferase complex OST-A for N-glycosylation and cell-surface localization. The tool compound NGI-1 inhibits OST...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 25;187(9):2209-2223.e16. doi: 10.1016/j.cell.2024.03.022.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Nuclear factor κB (NF-κB) plays roles in various diseases. Many inflammatory signals, such as circulating lipopolysaccharides (LPSs), activate NF-κB via specific receptors. Using whole-genome CRISPR-Cas9 screens of LPS-treated cells that express an NF-κB-driven suicide gene, we discovered that the LPS receptor Toll-like receptor 4 (TLR4) is specifically dependent on the oligosaccharyltransferase complex OST-A for N-glycosylation and cell-surface localization. The tool compound NGI-1 inhibits OST complexes in vivo, but the underlying molecular mechanism remained unknown. We did a CRISPR base-editor screen for NGI-1-resistant variants of STT3A, the catalytic subunit of OST-A. These variants, in conjunction with cryoelectron microscopy studies, revealed that NGI-1 binds the catalytic site of STT3A, where it traps a molecule of the donor substrate dolichyl-PP-GlcNAc<sub>2</sub>-Man<sub>9</sub>-Glc<sub>3</sub>, suggesting an uncompetitive inhibition mechanism. Our results provide a rationale for and an initial step toward the development of STT3A-specific inhibitors and illustrate the power of contemporaneous base-editor and structural studies to define drug mechanism of action.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38670073/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240501001029&v=2.18.0.post9+e462414">38670073</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.022>10.1016/j.cell.2024.03.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38670073</guid>
<pubDate>Fri, 26 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Benjamin L Lampson</dc:creator>
<dc:creator>Ana S Ramίrez</dc:creator>
<dc:creator>Marta Baro</dc:creator>
<dc:creator>Lixia He</dc:creator>
<dc:creator>Mudra Hegde</dc:creator>
<dc:creator>Vidyasagar Koduri</dc:creator>
<dc:creator>Jamie L Pfaff</dc:creator>
<dc:creator>Ruth E Hanna</dc:creator>
<dc:creator>Julia Kowal</dc:creator>
<dc:creator>Nitin H Shirole</dc:creator>
<dc:creator>Yanfeng He</dc:creator>
<dc:creator>John G Doench</dc:creator>
<dc:creator>Joseph N Contessa</dc:creator>
<dc:creator>Kaspar P Locher</dc:creator>
<dc:creator>William G Kaelin</dc:creator>
<dc:date>2024-04-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-κB</dc:title>
<dc:identifier>pmid:38670073</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.022</dc:identifier>
</item>





























</channel>
</rss>